Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RESIGNATION AND APPOINTMENT OF NON-EXECUTIVE DIRECTORS

The Board hereby announces that Mr. Hu Xubo ("**Mr. Hu**") has resigned as the non-executive Director and Mr. Zhou Mi ("**Mr. Zhou**") has been appointed as the non-executive Director, both with effect from 20 April 2018.

This announcement is made by the Board of Directors (the "**Directors**") (the "**Board**") of BBI Life Sciences Corporation (the "**Company**") pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**").

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The Board announces that Mr. Hu has resigned as the non-executive Director to focus more on his career, with effect from 20 April 2018. Mr. Hu confirmed that he has no disagreement with the Company and the Board, and there are no other matters in relation to his resignation as the non-executive Director that need to be brought to the attention of the Stock Exchange or the shareholders of the Company.

The Board wishes to express its sincere gratitude to Mr. Hu for his valuable contributions to the Company during his tenure of office.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

In light of Mr. Hu's departure, the Board is pleased to announce that the Company has appointed Mr. Zhou as the non-executive Director, with effect from 20 April 2018. The biography of Mr. Zhou is as follows:

Mr. Zhou Mi, aged 35, has joined Bio Basic Inc. since July 2007, and was appointed as a department director of the Company on 16 January 2014. In his role, he is responsible for the manufacture and sale in overseas market. Mr. Zhou graduated and obtained Bachelor of Science in Biochemistry from Carleton University in Ottawa, Canada in 2007.

As at the date of this announcement, Mr. Zhou holds 545,288 shares of the Company, representing approximately 0.10% of the total number of issued shares of the company.

Mr. Zhou's remuneration as the non-executive Director is CAD60,000 per year, which is determined by the Board according to the Company's relevant remuneration policies. Based on the articles of association of the Company, Mr. Zhou's tenure of office as the non-executive Director will expire upon the first general meeting following his appointment, and he is eligible for re-election at such meeting.

As at the date of the announcement, save as disclosed above, Mr. Zhou confirmed that he does not (i) hold any directorships in other public companies whose securities are listed on any securities market in Hong Kong or overseas in the past three years; (ii) have other major appointments or professional qualifications; (iii) have any relationship with any other Directors, senior management or substantial or controlling shareholders of the Company (within the meaning ascribed to it under the Listing Rules); (iv) have any other information that is required to be disclosed pursuant to Rule 13.51(2) (h) to (v) of the Listing Rules, and there are no other matters in relation to his appointment as the Non-executive Director that need to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to express its warm welcome to Mr. Zhou on his new position.

By order of the Board BBI Life Sciences Corporation Wang Qisong Chairman

Hong Kong, 20 April 2018

As at the date of this announcement, the Board comprises Mr. Wang Qisong, Ms. Wang Luojia and Ms. Wang Jin as executive Directors; Mr. Zhou Mi as non-executive Director; and Mr. Xia Lijun, Mr. Ho Kenneth Kai Chung and Mr. Liu Jianjun as independent non-executive Directors.